TheStreet.com's Jim Cramer says the Senate is filled with more-savvy politicians, and the upside for beaten-down names is huge.

Nancy Pelosi has now said her piece. The most unpopular Speaker of the House in the history of Wall Street has gotten her precious health care legislation through the House after ramming through a stimulus package that had far too little infrastructure and far too much pay raise for municipal and state workers, the most powerful interest group in the country.

But this time the Senate sees through it, and the politicians -- despite Pelosi's insistence that Tuesday's election went her way -- know better. There are pages after pages after pages in this bill that look threatening. But here's the rub: This bill's public option, the one that is supposed to be a killer to everything health care, should affect no more than 6 million people over a 10-year period, according to the Congressional Budget Office. In order to get 60 votes in the Senate, even that may prove to be too powerful an option.

Analyst upgrades:

• FBR Capital upgraded M&T Bank (NYSE: MTB) to Market Perform from Underperform following the Q3 results to reflect the company's improved earnings outlook and better credit trends. The firm has a $70 price target on shares.
• Kaufman Bros. upgraded Autodesk (NASDAQ: ADSK) to Buy from Hold as it believes a bottom has been reached in the manufacturing and construction industries. The firm raised its target on shares to $30 from $26.
• Goldman upgraded Caterpillar (NYSE: CAT) to Neutral from Sell and raised its target to $64 from $48 citing improved cost controls and construction outlook.
• Pentair (NYSE: PNR) was upgraded to Buy from Hold at KeyBanc.
• Lexmark (NYSE: LXK) was upgraded to Neutral from Underweight at JPMorgan.
• Stryker (NYSE: SYK) was upgraded to Neutral from Underperform at BofA/Merrill.

Analyst upgrades:

• Deutsche Bank upgraded Blackrock (NYSE: BLK) to Buy from Hold as it believes the BGI acquisition is becoming more accretive with the market rally and that the company's core trends are healthy. The firm raised its target on shares to $230 from $180.
• Citigroup upgraded Burlington Northern (NYSE: BNI) to Hold from Sell as it believes the risk/reward on shares is balanced based on 2010 estimates. Citi raised its target on shares to $89 from $75.
• Auriga upgraded Eclipsys (NASDAQ: ECLP) to Buy from Hold on expectations the company's margin expansion initiatives will drive benefits in 2010 and 2011. The firm raised its target on shares to $24 from $16.
• Seagate (NASDAQ: STX) was upgraded to Overweight from Market Weight at Thomas Weisel and to Buy from Hold at Deutsche Bank.
• Web.com (NASDAQ: WWWW) was upgraded to Outperform from Market Perform at FBR Capital.
• CenturyTel (NYSE: CTL) was upgraded to Overweight from Equal Weight at Morgan Stanley.

Analyst upgrades:

• Citigroup upgraded Advanced Micro (NYSE: AMD) to Buy from Hold and raised its target to $5.50 from $4.25 citing valuation and expectations for the company's competitive position and gross margins to improve.
• Barclays upgraded American Express (NYSE: AXP) to Overweight from Equal Weight citing long-term earnings growth as the company benefits from declining charge-offs and credit costs. The firm has a $38 target on the stock.
• JPMorgan upgraded Arch Coal (NYSE: ACI) to Overweight from Neutral and raised its target to $22 from $19 citing the FTC approval for the acquisition of Jacobs Ranch mine and valuation.
• Bebe Stores (NASDAQ: BEBE) was upgraded to Overweight from Equal Weight at Stephens.
• Cheesecake Factory (NASDAQ: CAKE) was upgraded to Neutral from Underweight at Piper Jaffray.
• Ashland (NYSE: ASH) was upgraded to Buy from Hold at KeyBanc.

TheStreet.com's Jim Cramer says there'll be a time to buy health care. But wait until the smoke clears.

Please don't tell me we are back in the world of no institutional memory again. That all that happened is we dropped enough points to freak everyone out, get the bears out of hibernation and then it is onward and upward. Nothing would shock me, especially the vehemence with which everyone hated the market again Monday.

If you replay what happened, most of the issues stemmed from statements made by the same Europeans that have said no more stimulus is needed, the same Europeans who have been in denial the whole way publicly, but believe me they have been stimulating like mad because their banks are a much larger size relative to their gross domestic product than ours and are in many ways worse off.

Analyst upgrades:

• Banc of America/Merrill upgraded Lincoln National (NYSE: LNC) to Buy from Underperform and raised its target to $17 from $10 citing expectations that the company will "qualify for and accept TARP funding."
  
• Credit Suisse upgraded AU Optronics (NYSE: AUO) to Outperform from Neutral as it believes inventory levels are low end demand is better than expected.
  
• JP Morgan upgraded Shaw Group (NYSE: SGR) to Overweight from Neutral. The firm views the recent pullback in shares as a buying opportunity given the company's attractive nuke position and expected ramp in government spending.
• Patterson-UTI Energy (NASDAQ: PTEN) was upgraded to Buy from Neutral at Goldman.
  
• Barrick Gold (NYSE: ABX) was raised to Overweight from Market Weight at Thomas Weisel.
  
• Stryker (NYSE: SYK) was lifted to Sector Perform from Underperform at RBC Capital.

Stryker (NYSE: SYK - option chain) stock is falling today after advisors to federal regulators recommended that the company's bone-growth putty for spinal surgery should not be approved for expanded use. The advisors were concerned about a lack of scientific rigor in SYK's clinical trials of the putty. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on SYK.

This morning, SYK opened at $33.55. So far today the stock has hit a low of $32.34 and a high of $33.89. As of 11:50, SYK is trading at $32.73, down $1.31 (-3.9%). The chart for SYK looks bullish and S&P gives SYK a positive 4 STARS (out of 5) buy ranking.

Earnings season was in full bloom this week, and BloggingStocks contributors often made their choices following a company's report. With the exception of very few, the conclusion was to stay away from most stocks, which says a lot about how companies did overall.

Still, there have been a select few that looked like good investment ideas even in these troubled times. So for those who can brave investing during such an earnings season, here are a few ideas from BloggingStocks contributors:

"Stryker (NYSE: SYK) is a bargain at 15.1x next 12-month EPS," says J. Royden Ward, editor of The Cabot Benjamin Graham Value Letter, a service which focuses on stocks that would be well-suited to the investing strategy of Ben Graham, legendary value investor and mentor to Warren Buffett.

"Stryker develops, manufactures and sells specialty surgical and medical products. Its orthopedic division makes hip, knee and other implants.

"SYK also makes a wide variety of medical products and instruments ranging from hospital beds to medical video cameras, surgical drills and saws, and instruments for implants.

Medtronic (NYSE: MDT) closed at $39.93. MDT is scheduled to report Q2 EPS on November 18. MDT November 40 straddle is priced at $3.50, December 40 is at $5.50. MDT December option implied volatility of 54 is above its 26-week average of 32 according to Track Data, suggesting larger price movement.

Covidien (NYSE: COV), a medical solutions device provider, closed at $37.07. COV is scheduled to report Q4 EPS on November 17. COV November 40 straddle is priced at $4.40, December 40 straddle is priced at $6.40. COV December option implied volatility of 58 is above its 26-week average of 32 according to Track Data, suggesting larger price movement.

Abbott Lab (NYSE: ABT) closed at $57.14. ABT December option implied volatility of 42 is above its 26-week average of 32 according to Track Data, suggesting larger price movement.

Stryker (NYSE: SYK), a medical technology company, closed at $47.70. SYK December option implied volatility of 60 is above its 26-week average of 32 according to Track Data, suggesting larger price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

MOST NOTEWORTHY: Stryker, General Dynamics and Garmin were today's noteworthy upgrades:

• Baird upgraded shares of Stryker (NYSE: SYK) to Outperform from Neutral as they believe the company's manufacturing problems are more manageable than expected and that supply constraints involving the Trident acetabular cup appear more limited.
  
• Wachovia raised General Dynamics (NYSE: GD) to Outperform from Market Perform, citing valuation, likely resumption in buybacks, and conservative guidance.
  
• Oppenheimer upgraded shares of Garmin (NASDAQ: GRMN) to Outperform from Perform on valuation, as they believe sentiment has troughed and that downward revisions are already priced into shares.

OTHER UPGRADES:

• Merrill raised Turkcell (NYSE: TKC) to Buy from Neutral.
  
• Lehman upgraded HealthSouth (NYSE: HLS) to Overweight from Underweight.
  
• Bear Stearns upgraded McAfee (NYSE: MFE) to Outperform from Peer Perform.

In a choppy/consolidating (or perhaps worse) market, discretion dictates that one looks for companies where the demographics are running in the company's favor. Health care services in the United States is one such sector, and in this category, Stryker Corp (NYSE: SYK) is worth an evaluation.

Stryker (NYSE: SYK) is a leading provider of artificial hip, prosthetic knee and trauma products.As one might sense, orthopedic implant demand is robust and looks to remain so in the immediate years ahead, and probably beyond. Not only because the U.S.'s population is aging, but also the population in key international markets.

Analysts see sustained, double-digit earnings growth driven by the above demand and by new product launches. Further, Stryker also has modest pricing power, and analysts also see market share gains in selected business segments. The Reuters F2007/F2008 EPS consensus estimates for SYK are $2.40/$2.88.

The risks? A negative change in Medicare reimbursement rates would hurt Stryker's results. The company also remains vulnerable to the emergence of a 'game changer' -- an innovative product launch by a competitor in one of its tech-intensive business lines.

The First Call mean rating for SYK is: Buy [22 firms]. Mean 2008 target: $82.00 [high: $90, low: $74].

Stock Analysis: Stryker is a moderate-risk stock not suitable for low-risk investors. Investors with an investment horizon longer than two years should be rewarded from SYK's shares. Sell / Stop Loss: $48.

General Electric (NYSE: GE) will report third quarter EPS on 10/12.

• Alex Brown says: "Given attractive risk/reward verses our $47 TP, we reiterate Buy."
  
• Investors and analysts have frequently called for the sale of NBC Universal because of its declining revenue and GE's 'Six Sigma' discipline not being compatible with Hollywood sensibilities.
  
• GE October option implied volatility of 24 is above its 26-week average of 20 according to Track Data, suggesting larger risk.

Stryker (NYSE: SYK), a medical technology company with a broad range of products in orthopedics and medical specialties, closed $73.14.

• SYK will report EPS on 10/17.
  
• SYK has been frequently subject to unconfirmed buyout chatter.
  
• SYK October option implied volatility of 34 is above its 26-week average of 25 according to Track Data, suggesting larger price fluctuations.

Daily options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Apple (NASDAQ: AAPL) volatility elevated at 42 into iPhone. AAPL's iPhone will be in stores on Friday June 29th. Thomas Weisel says: "Checks suggest Macs are strong; iPhone in, just as iPod seems to be peaking; raising estimates." AAPL is expected to report earnings in late July. AAPL July and August option implied volatility of 42 is above its 26-week average of 35 according to Track Data, suggesting larger risk.

Stryker (NYSE: SYK) implied volatility at elevated into 7/19 earnings and guidance. SYK, a medical technology company with a broad range of products in orthopedics and medical specialties, will report earnings on 7/19. Goldman Sachs CO says: "we are removing SYK from the Americas Investment Buy list. There is no change to our constructive stance on SYK, as the outlook for volume/pricing trends and free cash flow generation remains solid." SYK July option implied volatility of 24 is above its 26-week average of 21 according to Track Data, suggesting larger price fluctuations.

Option volume leaders today are: Dendreon (NASDAQ: DNDN) and General Motors (NYSE: GM).

Daily Option Update is provided by Stock Options Specialist Paul Foster of theflyonthewall.com.

Smith & Nephew plc (NYSE:SNN) announced the acquisition this morning of Swiss company Plus Orthopedics for $889 million in cash. This will solidify Smith & Nephew's position as the number 4 global player. The other three major firms are Stryker Corp. (NYSE:SYK), Zimmer Holdings (NYSE:ZMH), and soon to be acquired Biomet Inc. (NASDAQ:BMET). Biomet is undergoing due diligence by a group of private equity firms led by the Blackstone Group. The transaction is expected to close by October of this year.

The orthopedic sector has the wind at its back. The approval process for an orthopedic device is rigorous, but not as lengthy as the cardiac device sector. The marketplace is global in nature and the demographics are about to enter the sweet spot.

With 78 million U.S. baby boomers alone, and another 80 million-plus baby boomers in the European markets, the aging of this group is ripe for the sector. New hips, knees, elbows and shoulders will see record recipients as each year unfolds. Besides the basic joint-replacement products, the spinal sector is also expected to see massive growth. Minimally invasive surgical procedures are expanding the addressable market as the risk profile for such surgeries is significantly less. The dread of osteoporosis affects nearly 700,000 women in the United States alone.